P192 Personalizing treatment for predicting response to infliximab in children with Crohn’s disease using proteomic biomarkers
Harland S. Winter(Massachusetts General Hospital), Towia A. Libermann(Beth Israel Deaconess Medical Center), Mara A. Havard(Riley Hospital for Children), C Pursley(Massachusetts General Hospital), Joseph A. Picoraro(Columbia University Irving Medical Center), Robert N. Baldassano(Children's Hospital of Philadelphia), Prateek Wali(SUNY Upstate Medical University), Xihong Lin(Harvard University), Lisa W. Blystone(SUNY Upstate Medical University), Sofia G. Verstraete(University of California San Francisco Medical Center), Becca Trombler(University of California San Francisco Medical Center), M D Pfeffkorn(Riley Hospital for Children), M A Washek(Massachusetts General Hospital), W Mortan(Riley Hospital for Children), Xin Gu(Kunming University of Science and Technology), Naveen Kumar(Punjab Engineering College), Hasan H. Otu, Long Ngo(Trường ĐH Nguyễn Tất Thành), Simon T. Dillon(Beth Israel Deaconess Medical Center)
Cited by 1
Related Papers
Human gut microbiome viewed across age and geography
|Nature|2012|7.9k
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k